Nutriplex Omega Plus Injection

Adult administration

Administered via central venous catheter. The infusion rate is determined considering the total volume to be administered, the characteristics of the final mixed solution, the daily dosage, and administration time. Typically, the infusion amount is gradually increased over the first 30 minutes to reach an appropriate dosage. The maximum infusion rate should not exceed 2.0 mL/kg/hour. The maximum daily dosage is 40 mL per kg of the patient’s body weight. Depending on the patient's condition, caloric expenditure, and metabolism.

This medication must be used strictly according to a doctor's prescription and instructions. If serious allergic reactions such as anaphylaxis occur, administration should be discontinued immediately. It should not be mixed with specific medications such as Ceftriaxone, and care should be taken to not share the same infusion equipment. It may pose risks to premature and low-birth-weight infants; hence, use should be avoided. Do not administer to preterm infants under 2 years, neonates, infants, and specific allergy sufferers, patients with severe renal failure or liver disease. Administration should be cautious in patients with existing conditions such as renal failure, liver dysfunction, diabetes, etc., and blood lipid and electrolyte levels should be monitored regularly. During initial administration, various adverse reactions such as fever, chills, nausea, and difficulty breathing may occur, so careful observation is required. Side effects such as hypertriglyceridemia or fatty syndrome may occur; therefore, serum triglyceride levels should be routinely checked. This medication can affect blood coagulation, so patients with coagulation disorders should be particularly cautious. Before administration, the patient's hydration, electrolyte, and acid-base balance should be improved, and blood glucose and electrolyte levels should be continuously monitored during administration. There may be interactions with other medications, so it is crucial to consult an expert when adding new medications. The safety of this drug in pregnant or nursing women has not been established; it should be used only in special cases. It can affect blood test results following administration, so attention should be paid to the timing and method of testing. In the case of overdose, severe side effects may occur; administration should be discontinued immediately and appropriate treatment should be received. Do not use if the infusion bag is damaged, discolored, or contains foreign substances, and maintain strict aseptic techniques to prevent infection. Store in a sealed container to prevent exposure to air, and store at a temperature between 1 and 25 degrees Celsius, ensuring it does not freeze.

Serious side effects

Anaphylactic reactions (hives, severe swelling, chest tightness, difficulty breathing, cold sweat, paleness), severe skin adverse reactions (severe rashes, blisters, skin peeling, pain in oral/ocular mucosa), respiratory issues (difficulty breathing, cyanosis), liver issues (yellowing of skin or eyes (jaundice), systemic lethargy), severe neurological symptoms (severe headache, confusion, visual disturbances, paralysis), severe edema or urination abnormalities.

Mild side effects

• Slight fever
• warmth
• chills
• decreased appetite
• nausea
• vomiting
• headache
• back pain
• bone pain
• chest pain

This medication should be stored in a sealed container to prevent exposure to air and should be kept at temperatures between 1 to 25 degrees Celsius, avoiding freezing.

Appearance

An emulsion injection consisting of a lipid solution containing a white liquid in a transparent container, separated into three compartments: a colorless or pale yellow transparent dextrose and amino acid liquid.

Package unit

1,250 mL/bag, 1,875 mL/bag, 2,500 mL/bag